Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Maggie Li, E. Beck, Oliver Laeyendecker, et al.
Blood Advances (2022) Vol. 6, Iss. 12, pp. 3678-3683
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 125
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 83
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Lise J Estcourt, Claudia S. Cohn, Monica B. Pagano, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1310-1321
Open Access | Times Cited: 63
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 37
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of General Virology (2023) Vol. 104, Iss. 5
Open Access | Times Cited: 30
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
Karine Lacombe, Thomas Hueso, Raphaël Porcher, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000427-e000427
Open Access | Times Cited: 16
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 6
A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses
James T. Gordy, Yinan Hui, Courtney Schill, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching
J. Lee, Jaiprasath Sachithanandham, John S. Lee, et al.
Microbiology Spectrum (2025)
Open Access
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
Juan G. Ripoll, Ellen K. Gorman, Justin E. Juskewitch, et al.
Blood Advances (2022) Vol. 6, Iss. 23, pp. 5951-5955
Open Access | Times Cited: 24
Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
Scott A. McConnell, Jaiprasath Sachithanandham, Nathan J. Mudrak, et al.
Cell chemical biology (2023) Vol. 30, Iss. 7, pp. 726-738.e4
Open Access | Times Cited: 12
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
JCI Insight (2024) Vol. 9, Iss. 8
Open Access | Times Cited: 3
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 17
Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells
Alok Kumar Singh, Rulin Wang, Kara A. Lombardo, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107733-107733
Open Access | Times Cited: 9
Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19
Tsofia Inbar, Eldad J. Dann, Omer Kerner, et al.
Transfusion (2024) Vol. 64, Iss. 3, pp. 443-448
Closed Access | Times Cited: 2
Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease
Hyunah Yoon, Liise‐anne Pirofski
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 2
COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
David J. Sullivan, Arturo Casadevall
mBio (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 7
Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe
Maria R. Farcet, Michael Karbiener, Simone Knotzer, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1396-1400
Open Access | Times Cited: 11
Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
David J. Sullivan, Massimo Franchini, Michael J. Joyner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 15
Convalescent plasma and COVID‐19: Time for a second—second look?
Michael J. Joyner, Rickey E. Carter, DeLisa Fairweather, et al.
Transfusion Medicine (2022) Vol. 33, Iss. 1, pp. 16-20
Open Access | Times Cited: 10
Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
Armelle Otiniano, Zoé Van de Wyngaert, Éolia Brissot, et al.
Bone Marrow Transplantation (2022) Vol. 58, Iss. 3, pp. 340-342
Open Access | Times Cited: 10
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)
Taweegrit Siripongboonsitti, Nuttakant Nontawong, Kriangkrai Tawinprai, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 5
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2
Tom Lucaj, Ian Hay, Amirreza Samarbakhsh, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104126-104126
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top